Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286


Treatment of Lysosomal Storage Disorders (LSDs)

Author(s): ">Antonino Tuttolomondo

Volume 26 , Issue 40 , 2020

Page: [5087 - 5088] Pages: 2

DOI: 10.2174/138161282640201111114453

Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers 2018; 4(1): 27.
Sun A. Lysosomal storage disease overview. Ann Transl Med 2018; 6(24): 476.
Cohen IJ, Baris HN, Mistry PK, Sands MS. Treatment for Lsds: real options for several diseases. Forward. Pediatr Endocrinol Rev 2014; 12(Suppl. 1): 71.
Wong VW, Petta S, Hiriart JB, et al. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. J Hepatol 2017; 67(3): 577-84.
Petta S, Adinolfi LE, Fracanzani AL, et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 2018; 69(1): 18-24.
Petta S, Valenti L, Tuttolomondo A, et al. Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology 2017; 66(6): 1885-93.
Simonetta I, Tuttolomondo A, Daidone M, Miceli S, Pinto A. Treatment of Anderson-Fabry disease Current Pharmaceutical Design 2020 Online ahead of print 2020.
Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 2015; 10: 36.
Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 2013; 8: 47.
Weidemann F, Niemann M, Störk S, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 2013; 274(4): 331-41.
Kubaski F, Vairo F, Baldo G, Poswar FO, Corte AD, Giugliani R. Therapeutic options for mucopolysaccharidosis II (Hunter Disease). Current Pharmaceutical Design 2020. Online ahead of print. 2020.
Sheth J, Nair A. Treatment for lysosomal storage disorders Current Pharmaceutical Design 2020 Online ahead of print 2020.
Tuttolomondo A, Maida C, Pinto A. Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes. World J Orthop 2015; 6(1): 62-76.
Pinto A, Tuttolomondo A, Di Raimondo D, Fernandez P, Licata G. Risk factors profile and clinical outcome of ischemic stroke patients admitted in a Department of Internal Medicine and classified by TOAST classification. Int Angiol 2006; 25(3): 261-7.
Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute ischemic stroke. J Neuroinflammation 2019; 16(1): 88.

© 2022 Bentham Science Publishers | Privacy Policy